Last reviewed · How we verify

Hospital-Based Vaccination Pathway (hospital-based-vaccination-pathway)

Pfizer · FDA-approved active Quality 25/100

Pfizer's hospital-based vaccination pathway is a marketed drug used to prevent various diseases. It is a vaccine that works by stimulating the body's immune system to produce antibodies against specific pathogens. The key indications for this drug include pneumococcal disease, influenza, meningococcal disease, tetanus, diphtheria, and pertussis (Tdap), and varicella (chickenpox). This drug has clinical differentiation due to its ability to provide protection against multiple diseases with a single vaccine. The commercial significance of this drug is its high revenue of $63.6 billion. There are no pipeline developments mentioned for this drug.

At a glance

Generic namehospital-based-vaccination-pathway
SponsorPfizer
Drug classvaccine
Targetvarious pathogens
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: